Zachary T. Bloomgarden, MD, Editor of the Journal of Diabetes and a Clinical Professor at the Mount Sinai School of Medicine, provides a critical analysis of the recent FDA decision of keeping Avandia on the market.

Disclosures:
Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker